Blood pressure variability and risk of new-onset atrial fibrillation: A systematic review of randomized trials of antihypertensive drugs

Stroke

Volumn 41, Issue 9, 2010, Pages 2091-2093

  Webb, Alastair J S ^a   Rothwell, Peter M ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

atrial fibrillation; cardiac embolism; cerebrovascular accident; hypertension; prevention

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE VARIABILITY; CARDIAC PATIENT; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; HEART ATRIUM FIBRILLATION; HUMAN; META ANALYSIS; NEW ONSET ATRIAL FIBRILLATION; PRIORITY JOURNAL; RISK REDUCTION; STROKE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; VARIANCE; ATRIAL FIBRILLATION; BLOOD PRESSURE; DRUG EFFECTS; HYPERTENSION; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; RISK ASSESSMENT;

ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; BLOOD PRESSURE; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; RISK ASSESSMENT;

EID: 77956399308     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.589531     Document Type: Article

References (13)

1. Rothwell PM. Limitations of the usual BP hypothesis and importance of variability, instability, and episodic hypertension. Lancet. 2010;375: 938-948.
2. Rothwell PM, Howard SC, Dolan E. Prognostic significance of visit-to-visit variability, maximum systolic BP, and episodic hypertension. Lancet. 2010;375:895-905.
3. Rothwell PM, Howard SC, Dolan E. Effects of/3 blockers and calcium-channel blockers on within-individual variability in BP and risk of stroke. Lancet. 2010;9:469-480.
4. Webb AJS, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in BP and risk of stroke: a systematic review. Lancet. 2010;375:906-915.
5. Wachtell K, Lehto M, Gerdts E. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol. J Am Coll Card. 2005;45:712-719.
6. Schmieder RE, Kjeldsen SE, Julius S. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens. 2008;26:403-411.
7. Vagaonescu TD, Wilson AC, Kostis JB. Atrial fibrillation and isolated systolic hypertension: Systolic Hypertension in the Elderly Program. Hypertension. 2008;51:1552-1556.
8. Haywood LJ, Ford CE, Crow RS. Atrial fibrillation at baseline and during follow-up in ALLHAT. J Am Coll Card. 2009;54:2023-2031.
9. The ALLHAT Officers and Coordinators. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. JAMA. 2000;283:1967-1975.
10. Hansson L, Lindholm LH, Ekbom T. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the STOP-2 study. Lancet. 1999;354:1751-1756.
11. Hansson L, Lindholm LH, Niskanen L. Effect of angiotensin-converting- enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the CAPPP randomised trial. Lancet. 1999;353:611-616. (Pubitemid 29087980)
12. Marre M, Lièvre M, Chatellier G. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (DIABHYCAR study). BMJ. 2004;328:495-500.
13. Hansson L, Hedner T, Lund-Johansen P. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the NORDIL study. Lancet. 2000;356:359-365.